Press Releases

SEATTLE --(BUSINESS WIRE)--Dec. 23, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc . , an affiliate of Rayner Surgical Group Limited .

-- Transaction to Lock in Ongoing Revenue Stream for Omeros and Focus the Company on its Complement Franchise of MASP-2 and MASP-3 Inhibitors – -- Conference call today at 8:30 a.m. ET , 5:30 a.m. PT --   $125 million upfront payment and $200 million on achievement of commercial milestone Royalties

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Nov. 9, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

-- Data Show Improvement and Stabilization in Renal Function -- Unprecedented median proteinuria reduction of 64.4 percent seen in the narsoplimab Phase 2 clinical trial predicts a 41.6-year delay in need for dialysis compared to standard of care Narsoplimab is the first candidate targeting IgA

-- First Report of Narsoplimab’s Effects on Complement Activation Markers in Renal Disease Presented at the Annual Meeting of the American Society of Nephrology -- SEATTLE --(BUSINESS WIRE)--Nov. 5, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that the first report describing the

SEATTLE --(BUSINESS WIRE)--Nov. 4, 2021-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2021 , on Tuesday, November 9, 2021 , after the market closes.

-- Conference call today at 8:30 a.m. ET , 5:30 a.m. PT -- SEATTLE --(BUSINESS WIRE)--Oct. 18, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License

SEATTLE --(BUSINESS WIRE)--Oct. 1, 2021-- Omeros Corporation  (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA’s ongoing review of the company’s Biologics License Application (BLA) for narsoplimab in the treatment of

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 9, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Aug. 3, 2021-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021 , on Monday, August 9, 2021 , after the market closes. Omeros management will host a conference call and

-- Data on Organ Function Improvement Presented by Chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering -- SEATTLE --(BUSINESS WIRE)--Jun. 14, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab

-- Inhibitors of PDE7 Enzymes Could Treat Nicotine Abuse -- SEATTLE --(BUSINESS WIRE)--Jun. 10, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as

SEATTLE --(BUSINESS WIRE)--Jun. 9, 2021-- Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week. The fireside chat with Bank of America analyst, Geoff

-- Results show good safety and PK/PD profile consistent with low-dose, once-monthly subcutaneous dosing -- SEATTLE --(BUSINESS WIRE)--Jun. 9, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing

-- Study Patients Comprise Second Cohort from Bergamo, Italy -- SEATTLE --(BUSINESS WIRE)--May 28, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market

-- PDUFA Date is October 17, 2021 -- SEATTLE --(BUSINESS WIRE)--May 20, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--May 13, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 10, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--May 5, 2021-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021 , on Monday, May 10, 2021 , after the market closes. Omeros management will host a conference call and

SEATTLE --(BUSINESS WIRE)--May 4, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention ( CDC ) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated

-- Adaptive Platform Trial is Evaluating Drugs and Investigational Products in the Treatment of Critically Ill COVID-19 Patients -- SEATTLE & SAN FRANCISCO --(BUSINESS WIRE)--Mar. 23, 2021-- Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Feb. 25, 2021-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020 , on Monday, March 1, 2021 , after the market closes.

SEATTLE --(BUSINESS WIRE)--Jan. 26, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial

-- FDA sets PDUFA date of July 17, 2021 -- SEATTLE --(BUSINESS WIRE)--Jan. 19, 2021-- Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy

SEATTLE --(BUSINESS WIRE)--Jan. 11, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference this week. This conference is being held as a virtual conference